Free Trial
→ Stunning new initiative unfolding in the White House? (From Paradigm Press) (Ad)tc pixel

Judah Frommer Analyst Performance

Analyst at Morgan Stanley

Judah Frommer is a stock analyst at Morgan Stanley across a range of sectors, covering 20 publicly traded companies. Over the past year, Judah Frommer has issued 11 stock ratings, including buy, hold, and sell recommendations. While full access to Judah Frommer's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Judah Frommer's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Analyst Rating
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
66 Last 7 Years
Buy Recommendations
56.06% 37 Buy Ratings
Companies Covered
20 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy56.1%37 ratings
Hold40.9%27 ratings
Sell3.0%2 ratings

Out of 66 total stock ratings issued by Judah Frommer at Morgan Stanley, the majority (56.1%) have been Buy recommendations, followed by 40.9% Hold and 3.0% Sell.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
65.0% of companies on NASDAQ
13 companies
NYSE
35.0% of companies on NYSE
7 companies

Judah Frommer, an analyst at Morgan Stanley, currently covers 20 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
9 companies		45.0%
Consumer Staples
6 companies		30.0%
Retail/Wholesale
5 companies		25.0%

Judah Frommer of Morgan Stanley specializes in stock coverage within the Medical sector, with additional focus on Consumer Staples and Retail/Wholesale companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
7 companies		35.0%
CONS PD - MISC STPL
2 companies		10.0%
RETAIL - DISCOUNT
2 companies		10.0%
FOOD - MISC/DIVERSIFIED
2 companies		10.0%
MED - DRUGS
1 company		5.0%
MED - OUTP/HM CRE
1 company		5.0%
RETAIL - MISC/DIV
1 company		5.0%
RETAIL - SUPERMKT
1 company		5.0%
FOOD ITEMS - WHLE
1 company		5.0%
GROCERIES, GENERAL LINE
1 company		5.0%
GROCERY STORES
1 company		5.0%

Judah Frommer's Ratings History at Morgan Stanley

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export to Excel
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
9/12/2025Boost Price Target$83.12$101.00Overweight
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
8/21/2025Initiated Coverage$7.42$18.00Overweight
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
7/2/2025Boost Price Target$18.25$26.00Equal Weight
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
6/5/2025Boost Price Target$127.99$129.00Equal Weight
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
5/9/2025Lower Price Target$18.79$43.00Overweight
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
3/20/2025Initiated Coverage$19.95$46.00Overweight
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
3/20/2025Reiterated Rating$6.84$12.00Equal Weight
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
3/20/2025Initiated Coverage$90.53$100.00Equal Weight
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
3/14/2025Boost Price Target$6.55$24.00Overweight
Galapagos NV stock logo
GLPG
Galapagos
2/14/2025Downgrade$25.49$22.00Underweight
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
1/13/2025Lower Price Target$4.80$6.00Underweight
Today's Ratings
Top-Rated Stocks
More Ratings Tools